Wolfe Research initiated coverage of Alkermes (ALKS) with an Outperform rating and $45 price target calling it “a story still unfolding” and highlighting the company’s emerging narcolepsy franchise.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALKS:
- Alkermes price target raised to $34 from $33 at BofA
- Alkermes Completes Avadel Acquisition, Expands Sleep Medicine Portfolio
- Irish High Court sanctions Avadel Pharmaceuticals acquisition by Alkermes
- ALKS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- 3 Best Value Stocks with Over 20% Upside in 2026, According to Analysts